Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Company Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Key Stats

• Today's Range: $4.23 to $4.93
• 50-Day Range: $2.94 to $6.95
• 52-Week Range: $1.98 to $7.95
• Volume: 96,772 shs
• Average Volume: 187,947 shs
• Market Capitalization: $32.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.82
• Consensus Rating: Moderate Buy

Vivos Therapeutics Stock Analysis - MarketRank™

Vivos Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 884th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vivos Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivos Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivos Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivos Therapeutics has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.89% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 18.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivos Therapeutics does not currently pay a dividend.

Dividend Growth

Vivos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.89% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 18.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Vivos Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vivos Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Vivos Therapeutics is held by insiders.

Percentage Held by Institutions

Only 26.35% of the stock of Vivos Therapeutics is held by institutions.

VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed this year?

Vivos Therapeutics' stock was trading at $4.29 at the beginning of the year. Since then, VVOS shares have increased by 0.9% and is now trading at $4.33.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its quarterly earnings results on Tuesday, August, 19th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.16. The firm had revenue of $3.82 million for the quarter, compared to the consensus estimate of $3.37 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 232.76% and a negative net margin of 99.49%.
Read the conference call transcript.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics shares reverse split on the morning of Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Who are Vivos Therapeutics' major shareholders?

Top institutional shareholders of Vivos Therapeutics include B. Riley Wealth Advisors Inc. (1.18%) and XTX Topco Ltd (0.35%).
View institutional ownership trends.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vivos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 8/30/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VVOS
• CIK: 1716166
• Web: www.vivoslife.com
• Phone: 866-908-4867
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vivos Therapeutics: $4.82
• High Price Target: $6.20
• Low Price Target: $2.25
• Potential Upside/Downside: +11.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.14 million
• Net Margins: -99.49%
• Pretax Margin: -99.49%
• Return on Equity: -232.76%
• Return on Assets: -84.30%

Debt

• Debt-to-Equity Ratio: 1.69
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $15.03 million
• Price / Sales: 2.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 7.10

Miscellaneous

• Outstanding Shares: 7,500,000
• Free Float: 7,280,000
• Market Cap: $32.48 million
• Optionable: Optionable
• Beta: 7.03